Trial intelligence / Profile preview

Phase II lazertinib in treatment-naive EGFR-mutated NSCLC with brain metastases

KCT0006951Phase 2Not yet recruiting

Sponsor

Yuhan

Start

Mar 2022

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1